Cell Biosci takes $15M to examine cell pathways
Cell Biosciences, maker of software and other tools to learn more about how cells move and interact, has brought in $15 million of an anticipated $17.6 million fourth round of funding, according to a filing with the SEC. Based in Santa Clara, Calif., the company is backed by Domain Associates, Latterell Venture Partners, Vertical Group, Wellcome Trust, Novo A/S and the Royal Bank of Canada.
Cell Biosciences to launch new tech with $10M
Cell Biosciences announced that it’s just brought in $10 million in a third round of funding to launch its new protein analysis technology used to track cellular pathways. It plans to sell its products to labs and research institutions that are developing medications and chemical diagnostics for cancer, diabetes and other diseases.
The Palo Alto, Calif. company has scheduled the launch for its new technology at the end of this month. A previous version of the… Continue Reading
Life sciences briefing: Tuesday, Aug. 21, 2007
(UPDATED at 7:40pm PT: See below.)
Featured companies: Adnexus Therapeutics, BioForm Medical, Confirma, Cardiovascular Systems, Mirabilis Medica, Neuromed Pharmaceuticals, PlaCor, Seno Medical Instruments, Vibrynt
BioForm Medical files $115M IPO for “medical aesthetics” — BioForm Medical, a San Mateo, Calif., developer of wrinkle fillers and other products for cosmetic procedures, filed to raise $115 million in an initial offering. BioForm’s major customers are plastic surgeons and dermatologists.
BioForm, however, takes pains to describe itself differently on its Web site…. Continue Reading